1. A HEAD‐TO‐HEAD PHASE 3 STUDY COMPARING BGB‐3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA. (June 2017) Authors: Buske, C.; LeBlond, V.; Novotny, W.; Owen, R.; Tedeschi, A.; Atwal, S.; Cohen, A.; Huang, J.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 422 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. (October 2022) Authors: Hong, D.; Shergill, A.; Bazhenova, L.; Cho, B.C.; Heist, R.; Moreno, V.; Falchook, G.S.; Nagasaka, M.; Cassier, P.; Besse, B.; Kim, D.W.; Yoon, S.; Le, X.; Zhao, T.; Atwal, S.; Park, E.; Lee, J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). (12th June 2019) Authors: Tam, C.S.; Wang, M.; Simpson, D.; Opat, S.; Cull, G.; Munoz, J.; Phillips, T.J.; Kim, W.; Atwal, S.; Wei, R.; Huang, J.; Elstrom, R.; Trotman, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗